D-glucose

Overview

Glucose is a simple sugar (monosaccharide) generated during phosynthesis involving water, carbon and sunlight in plants. It is produced in humans via hepatic gluconeogenesis and breakdown of polymeric glucose forms (glycogenolysis). It circulates in human circulation as blood glucose and acts as an essential energy source for many organisms through aerobic or anaerobic respiration and fermentation. It is primarily stored as starch in plants and glycogen in animals to be used in various metabolic processes in the cellular level. Its aldohexose stereoisomer, dextrose or D-glucose, is the most commonly occurring isomer of glucose in nature. L-glucose is a synthesized enantiomer that is used as a low-calorie sweetener and laxative. The unspecified form of glucose is commonly supplied as an injection for nutritional supplementation or metabolic disorders where glucose levels are improperly regulated. Glucose is listed on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system.

Indication

Glucose pharmaceutical formulations (oral tablets, injections) are indicated for caloric supply and carbohydrate supplementation in case of nutrient deprivation. It is also used for metabolic disorders such as hypoglycemia.

Associated Conditions

Dehydration
End-stage Chronic Kidney Failure
Fluid Loss
Hypoglycemia
Local Anaesthesia therapy
Potassium imbalance

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Human Models of Selective Insulin Resistance: Pancreatic Clamp	2024/08/16	NCT06558422	Phase 1	Not yet recruiting	Columbia University
Human Models of Selective Insulin Resistance: Alpelisib, Part I	2024/04/09	NCT06354088	Phase 1	Recruiting	Columbia University
Dexamethasone/Pancreatic Clamp P&F	2023/11/13	NCT06126354	Phase 1	Withdrawn	Columbia University
Pancreatic Clamp in NAFLD	2023/02/13	NCT05724134	Phase 1	Suspended	Columbia University
The Application of Glucose CEST MR Imaging in Brain Tumor	2021/06/30	NCT04945499	Early Phase 1	UNKNOWN	Zhujiang Hospital

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Haemonetics Anticoagulant Citrate Phosphate Double Dextrose Solution (CP2D)	Haemonetics Corporation	57826-455	EXTRACORPOREAL	464 mg in 1 mL	9/30/2020
Elliotts B	QOL Medical, LLC	67871-007	INTRATHECAL	8 mg in 10 mL	3/20/2012
Elliotts B	Lukare Medical, LLC	55792-007	INTRATHECAL	8 mg in 10 mL	11/16/2018
Haemonetics Additive Solution Formula 3 (AS-3)	Haemonetics Corporation	57826-460	EXTRACORPOREAL	100 mg in 1 mL	9/11/2020

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
DIANEAL PD-2 PERITONEAL DIALYSIS SOLUTION WITH 4.25% DEXTROSE	BAXTER HEALTHCARE SA, SINGAPORE BRANCH, BAXTER HEALTHCARE CORPN	SIN05589P	SOLUTION, STERILE	4.25 g/100 ml	3/27/1991
DIANEAL LOW CALCIUM (2.5 mEq/l) PERITONEAL DIALYSIS SOLUTION WITH 1.5% DEXTROSE	BAXTER HEALTHCARE SA, SINGAPORE BRANCH, BAXTER HEALTHCARE CORPORATION	SIN06627P	SOLUTION, STERILE	1.5 g/100 ml	10/14/1991
DEXTROSE INJECTION USP 70%	BAXTER HEALTHCARE CORPORATION	SIN10166P	INJECTION	70 g/100 ml	10/6/1998
DIANEAL PD-2 PERITONEAL DIALYSIS SOLUTION WITH 1.5% DEXTROSE	BAXTER HEALTHCARE SA, SINGAPORE BRANCH, BAXTER HEALTHCARE CORPN	SIN05590P	SOLUTION, STERILE	1.5 g/100 ml	3/27/1991
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% INJECTION USP	BAXTER HEALTHCARE CORPORATION	SIN05730P	INJECTION	5 g/100 ml	4/8/1991
PERIOLIMEL N4E Emulsion for Infusion	Ajinomoto Health & Nutrition North America Inc. (Intermediate), Baxter S.A	SIN16888P	EMULSION	75.0g/L	10/20/2023
OLIMEL N9E Emulsion for Infusion	Ajinomoto Health & Nutrition North America Inc. (Intermediate), Baxter S.A	SIN16890P	EMULSION	110.0g/L	10/20/2023
10 mEq Potassium Chloride in 5% Dextrose and 0.33% Sodium Chloride Injection, USP	Baxter Healthcare Corporation, Baxter Healthcare Philippines, Inc.	SIN13224P	INJECTION	50 g/L	11/28/2006
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% INJECTION USP	Baxter Healthcare Corporation, North Cove Plant, BAXTER HEALTHCARE PHILIPPINES INC	SIN05731P	INJECTION	5 g/100 ml	4/8/1991
DIANEAL LOW CALCIUM (2.5 mEq/l) PERITONEAL DIALYSIS SOLUTION WITH 4.25% DEXTROSE	BAXTER HEALTHCARE SA, SINGAPORE BRANCH, BAXTER HEALTHCARE CORPORATION	SIN06625P	SOLUTION, STERILE	4.25 g/100 ml	10/14/1991

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access